Methylation status and protein expression of RASSF1A in endometriosis

Wu,Yu; Zhang,Mingde; Zhang,Xian; Xu,Zhenzhou; Jin,Weiguo

doi:10.3892/ol.2016.4512

Methylation status and protein expression of RASSF1A in endometriosis

Authors:
- Yu Wu
- Mingde Zhang
- Xian Zhang
- Zhenzhou Xu
- Weiguo Jin
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Liaocheng People's Hospital, Liaocheng Clinical School of Taishan Medical University, Liaocheng, Shangdong 252000, P.R. China, Department of Ear and Throat, Dongchang People's Hospital, Liaocheng, Shangdong 252000, P.R. China
Published online on: April 28, 2016 https://doi.org/10.3892/ol.2016.4512
Pages: 4107-4112

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ras association domain family 1A (RASSF1A) gene inactivation by promoter hypermethylation is a common event in the development of a variety of types of human cancer. Accumulated evidence has demonstrated that DNA methylation serve a critical role in the pathogenesis of endometriosis. The aim of the present study was to analyze the methylation status and protein expression of RASSF1A in endometriosis (EMS). The ectopic and corresponding eutopic endometrium tissues were collected from 45 women with EMS (EMS group) and normal endometrium tissues from 20 women without EMS (control group). The methylation status of RASSF1A was examined by methylation specific polymerase chain reaction (MSP). Immunohistochemistry was performed to measure RASSF1A protein level in endometrium tissues. In normal endometrium samples, RASSF1A protein expression was significantly higher at the secretory phase than the proliferative phase. RASSF1A protein expression in the ectopic endometrium tissues and eutopic endometrium tissues were significantly reduced than in normal endometrium (P<0.05). The frequency of aberrant methylation of RASSF1A was 55.56% in ectopic endometrium and 33.33% in paired eutopic endometrium, whereas such methylation was not detected in normal endometrium. Moreover, RASSF1A promoter hypermethylation was frequently associated with reduced expression of RASSF1A, and was common in advanced stage in ectopic endometrium of EMS. Epigenetic inactivation of RASSF1A through aberrant promoter methylation may be important in the formation and progression of EMS, and assessment of RASSF1A methylation status in eutopic endometrium may be a potentially useful biomarker to enhance the early detection of EMS.

View Figures

View References

1.	Giudice LC and Kao LC: Endometriosis. Lancet. 364:1789–1799. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Farquhar C: Endometriosis. BMJ. 334:249–253. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Sampson JA: Ovarian hematomas of endometrial type (perforating hemorrhagic cysts of the ovary) and implantation adenomas of endometrial type. Boston Med Surg J. 186:445–456. 1922. View Article : Google Scholar
4.	Dammann R, Yang G and Pfeifer GP: Hypermethylation of the cpG island of Ras association domain family 1A(RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res. 61:3105–3109. 2001.PubMed/NCBI
5.	Agathanggelou A, Honorio S, Macartney DP, et al: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 20:1509–1518. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Jo H, Kim JW, Kang GH, et al: Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol Res. 16:205–209. 2006.PubMed/NCBI
7.	Kuzmin I, Liu L, Dammann R, et al: Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res. 63:1888–1893. 2003.PubMed/NCBI
8.	Burbee DG, Forgacs E, Zöchbauer-Müller S, et al: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Starzinski-Powitz A, Gaetje R, Zeitvogel A, et al: Tracing cellular and molecular mechanisms involved in endometriosis. Hum Reprod Update. 4:724–729. 1998. View Article : Google Scholar : PubMed/NCBI
10.	Wu Y, Strawn E, Basir Z, Halverson G and Guo SW: Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics. 1:106–111. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Wu Y, Strawn E, Basir Z, Halverson G and Guo SW: Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in women with endometriosis. Fertil Steril. 87:24–32. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Canis M, Donnez JG, Guzick DS, et al: Revised American Society for Reproductive Medicine classification of endometriosis:1996. Fertil Steril. 67:817–821. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Darehdori AS, Dastjerdi MN, Dahim H, et al: Lack of significance of the BRCA2 promoter methylation status in different genotypes of the MTHFR a1298c polymorphism in ovarian cancer cases in Iran. Asian Pac J Cancer Prev. 13:1833–1836. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Wu Y, Zhang X, Lin L, et al: Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev. 15:1171–1176. 2014. View Article : Google Scholar : PubMed/NCBI
15.	Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature. 447:433–440. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Feinberg AP: Epigenetics at the epicenter of modern medicine. JAMA. 299:1345–1350. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Monte NM, Webster KA, Neuberg D, Dressler GR and Mutter GL: Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res. 70:6225–6232. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Zhang H, Zhao X, Liu S, Li J, Wen Z and Li M: 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappаB-dependent pathway. Mol Cell Endocrinol. 317:31–43. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Pallarés J, Velasco A, Eritja N, et al: Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol. 21:691–699. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Wang D, Chen Q, Zhang C, Ren F and Li T: DNA hypomethylation of the COX-2 gene promoter is associated with up-regulation of its mRNA expression in eutopic endometrium of endometriosis. Eur J Med Res. 17:1–6. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Byun DS, Lee MG, Chae KS, Ryu BG and Chi SG: Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res. 61:7034–7038. 2001.PubMed/NCBI
22.	Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61:8659–8663. 2001.PubMed/NCBI
23.	Kuroki T, Trapasso F, Yendamuri S, et al: Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res. 9:1441–1445. 2003.PubMed/NCBI
24.	Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
25.	Nasu K, Kawano Y, Tsukamoto Y, et al: Aberrant DNA methylation status of endometriosis: Epigenetics as the pathogenesis, biomarker and therapeutic target. J Obstet Gynaecol Res. 37:683–695. 2011. View Article : Google Scholar : PubMed/NCBI
26.	Balch C, Yan P, Craft T, et al: Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther. 4:1505–1514. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Kang S, Lee JM, Jeon ES, et al: RASSF1A hepermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer. 119:1316–1321. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Donninger H, Vos MD and Clark GJ: The RASSF1A tumor suppressor. J Cell Sci. 120:3163–3172. 2007. View Article : Google Scholar : PubMed/NCBI